drugset / Trial / NCT02073838
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a research study of ribavirin which will be given in combination with vismodegib and/or decitabine. The purpose of this study is to see if patients respond to treatment when ribavirin is given with vismodegib alone or in combination with decitabine.
Timeline
- Start
- 2015-05
- Primary completion
- 2022-11
- Completion
- 2022-11
Publications
- Mazewski C, Platanias LC. A novel approach to overcome drug resistance in acute myeloid leukemia. Haematologica. 2023 Nov 1;108(11):2889-2890. doi: 10.3324/haematol.2023.283099. No abstract available.
- Assouline S, Gasiorek J, Bergeron J, Lambert C, Culjkovic-Kraljacic B, Cocolakis E, Zakaria C, Szlachtycz D, Yee K, Borden KLB. Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine. Haematologica. 2023 Nov 1;108(11):2946-2958. doi: 10.3324/haematol.2023.282791.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Ribavirin | Small molecule | 1400 mg | — |
| Subject | Vismodegib | Small molecule | 150 mg | — |